ArticleCirculation2025

Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation Receiving Oral Antiplatelet Therapy: Definitely Safe, but How Effective?

Philippe Gabriel Steg et al.PubMed ↗Publisher ↗

No numbers read from the abstract.